MARGINAL ZONE LYMPHOMA

This study compares a very low dose of radiation (4 Gy) to the standard dose (24 Gy) for people with follicular or marginal zone lymphoma, which are slow-growing but potentially curable. Researchers want to see if the low dose works just as well to control the cancer and prevent …

This study tests a new vaccine (EO2463) designed to train the immune system to attack lymphoma cells. It is for people with follicular or marginal zone lymphoma, either newly diagnosed or after prior treatment. The vaccine is given alone or with standard drugs to find the safest …

This study tests whether a combination of two drugs, Mosunetuzumab and Lenalidomide, works better than standard treatments for people with marginal zone lymphoma that has returned or not responded to prior therapy. About 260 adults who have had 1 to 3 prior treatments will be ran…

This study tests whether combining rituximab (an antibody) with venetoclax (a targeted inhibitor) can effectively treat people newly diagnosed with marginal zone lymphoma, a slow-growing blood cancer. About 33 participants will receive the drug combo, and researchers will measure…

This study tests a drug called orelabrutinib in 30 people with a slow-growing blood cancer called marginal zone lymphoma who have not had any prior treatment. The goal is to see if the drug can shrink or control the cancer. Participants take the drug by mouth and are monitored fo…

This early-stage study tests a new drug called AC676 in about 60 adults with certain blood cancers (like CLL, MCL, or DLBCL) that have returned or stopped responding to prior treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look…

This early-stage trial tests a therapy made from a patient's own immune cells, which are genetically modified to find and attack cancer cells. It is for people with several types of Non-Hodgkin lymphoma that have not responded to other treatments. The main goal is to check if the…

This early-stage study tests an experimental drug called ABBV-291 in adults with Non-Hodgkin's lymphoma that has come back or not responded to treatment. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 165 participants will rec…

This study tests a two-drug approach for adults newly diagnosed with follicular or marginal zone lymphoma, types of B-cell lymphoma. Participants first receive mosunetuzumab alone, then may get lenalidomide added if the cancer only partially responds. The goal is to see how many …

This study tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells. It is for adults with B cell cancers like lymphoma or leukemia that have come back or not responded to prior treatments. The goal is to see if this therapy is safe and eff…

This study compares two drug combinations in adults with follicular or marginal zone lymphoma that has returned or not responded to prior treatment. One group receives zanubrutinib plus obinutuzumab or rituximab, while the other gets lenalidomide plus rituximab. The goal is to se…

This early-phase study tests a new treatment for adults with certain types of blood cancer (like lymphoma) that have come back or not responded to standard therapies. The treatment combines a targeted drug (pirtobrutinib) with specially engineered immune cells (CAR T-cells) desig…

This study tests an oral drug called AS-1763 in adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other B-cell non-Hodgkin lymphomas who have already tried at least two prior treatments. The main goals are to find the safest dose and see how well the drug c…

This study tests a drug called loncastuximab tesirine in 50 adults with marginal zone lymphoma that has returned or not responded to prior therapy. The goal is to see if the drug can shrink or eliminate the cancer. Participants receive the drug intravenously, and researchers moni…

This study tests whether adding a targeted drug called polatuzumab vedotin after a stem cell transplant can safely control B-cell and Hodgkin lymphoma. About 20 adults whose lymphoma has returned or not responded to prior treatment will take part. The goal is to see if the drug c…

This early-stage study tests an experimental oral drug, LP-168, in about 60 people with certain blood cancers (like CLL, lymphoma) that have returned or not responded to prior treatments. The main goals are to find the safest dose and understand how the drug works in the body. Re…

This study tests an experimental oral drug called MK-1026 (nemtabrutinib) in people with certain blood cancers, including chronic lymphocytic leukemia, non-Hodgkin lymphoma, and Waldenstrom's macroglobulinemia. The goal is to see if the drug can shrink or control the cancer and t…

This study tests whether two drugs, pirtobrutinib and rituximab, can shrink or eliminate tumors in people newly diagnosed with marginal zone lymphoma. About 23 adults will receive the combination and be checked for response after several cycles. The goal is to control the disease…

This study tests an investigational drug called epcoritamab in 25 adults with newly diagnosed marginal zone lymphoma (MZL), a slow-growing blood cancer. The goal is to see if the drug can shrink or eliminate the cancer. Participants must not have received prior treatment for MZL.…

This study tests whether a combination of three drugs (epcoritamab, zanubrutinib, and rituximab) can safely shrink tumors in people with follicular lymphoma or marginal zone lymphoma that has come back or not responded to prior treatment. About 45 adults who have already tried at…

This study is testing an experimental drug called BGB-16673 for people with certain B-cell blood cancers (like lymphoma and leukemia) that have come back or not responded to other treatments. The drug works by breaking down a protein that helps these cancer cells grow. The trial …

This study tests a drug called pemigatinib in adults with certain types of B-cell non-Hodgkin lymphoma that have come back or not responded to at least two prior treatments. The goal is to see if the drug can shrink tumors and help control the disease. About 27 people will take p…

This early-stage study tests a new gene therapy called VNX-101 for people with blood cancers (like some leukemias and lymphomas) that have returned or not responded to standard treatments. The therapy uses a harmless virus to deliver a gene that helps the immune system target and…

This early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The main go…

This study is testing a combination of two drugs, zanubrutinib and rituximab, as the first treatment for people with marginal zone lymphoma, a slow-growing blood cancer. About 30 participants will receive the combo to see how well it shrinks tumors and how safe it is. The goal is…

This study looks at how often high blood pressure happens in people with certain blood cancers (like CLL or lymphoma) who are taking a type of targeted drug called a BTK inhibitor. The goal is to see if carefully managing that high blood pressure can reduce the risk of serious he…

This early-phase study tests a new type of immune cell therapy (CAR T cells) that targets two proteins, CD79b and CD19, on lymphoma cells. It is for people with non-Hodgkin lymphoma whose cancer has returned or stopped responding to standard treatments. The main goals are to chec…

This study tests a new treatment called CTX112 for people with B-cell blood cancers (like lymphoma or leukemia) that have not responded to standard therapy or have returned. CTX112 uses CRISPR gene-editing to create donor T-cells that can target and kill cancer cells. The trial w…

This study tests a combination of two drugs, acalabrutinib and obinutuzumab, in people with untreated slow-growing lymphomas like follicular lymphoma. The goal is to see if this treatment can shrink or control the cancer. About 49 adults will take part, and researchers will monit…

This study tests a new drug, BGB-16673, that destroys a protein cancer cells need to survive. It is for people with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to other treatments. The goal is to find the best dose and see if it shrinks …

This study tests a combination of two drugs, rituximab and zanubrutinib, in people with untreated follicular lymphoma or marginal zone lymphoma. The goal is to see how well the combo works and if it is safe. About 43 participants will receive the treatment, and researchers will m…

This study tests a new drug, orelabrutinib, combined with chemotherapy for people newly diagnosed with marginal zone lymphoma, a rare blood cancer. About 69 participants will receive the treatment to see if it improves tumor shrinkage and helps control the disease long-term. The …

This study follows 150 adults aged 70 and older with low-grade non-Hodgkin lymphoma to see how their quality of life changes during treatment. Researchers will use questionnaires to track well-being from diagnosis through one year after therapy starts. The goal is to identify whi…

This study follows about 705 adults with Waldenström's macroglobulinemia, chronic lymphocytic leukemia, marginal zone lymphoma, or follicular lymphoma who are already taking or starting zanubrutinib. Researchers will track hospital visits, emergency room use, and quality of life …

This study will follow 2,500 people recently diagnosed with marginal zone B-cell lymphoma to learn more about the disease and how different treatments work. Participants will provide blood and tissue samples and be monitored for years. The goal is to better understand the conditi…

This study is testing whether an artificial intelligence (AI) tool can help match cancer patients with the right clinical trials. Researchers will enroll up to 50,000 people with various cancers to see if the AI improves trial enrollment rates and patient outcomes. The goal is to…